Pharmaceutical Business review

Diamics cervical cancer test receives European approval

Comprised of the Pap-Map Cervical Cancer Collector, the Pap-Map Handle and the Transfer Station, the system allows the clinician to painlessly capture 360 degrees of cervical material and transfer the cells, with their spatial orientation intact, to a slide to support localization of identified lesions in both initial diagnosis and follow-up treatments.

Peter Gombrich, CEO of Diamics, said: “This CE Mark registration is a clear milestone for Diamics as it opens the door for commercialization of the system throughout the EU and other areas to help improve the detection of cervical cancer.”

Exit mobile version